Explainable machine learning prediction of edema adverse events in patients treated with tepotinib by Federico Amato, Rainer Strotmann, Roberto Castello, Rolf Bruns, Vishal Ghori, Andreas Johne, Karin Berghoff, Karthik Venkatakrishnan, Nadia Terranova

Connect to this object online.

Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers by Andreas Becker, Emily C. Martin, David Y. Mitchell, Roland Grenningloh, Andrew T. Bender, Julien Laurent, Harald Mackenzie, Andreas Johne

Connect to this object online.

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose by Wenyuan Xiong, Manja Friese‐Hamim, Andreas Johne, Christopher Stroh, Manfred Klevesath, Gerald S. Falchook, David S. Hong, Pascal Girard, Samer El Bawab

Connect to this object online.

Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study by Dina Oksen, Patricia Prince, Emmanuelle Boutmy, Elizabeth M. Garry, Barbara Ellers‐Lenz, Adina Estrin, Andreas Johne, Patrice Verpillat, Nicolle M. Gatto

Connect to this object online.